Literature DB >> 19012301

Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion.

Verónica Ferreiro1, Florencia Giliberto, García M Noelia Muñiz, Liliana Francipane, Diego M Marzese, Alejandra Mampel, María Roqué, Gustavo D Frechtel, Irene Szijan.   

Abstract

We report a Becker muscular dystrophy (BMD) family with one 5-year-old affected patient and a 69-year-old asymptomatic grandfather. Dystrophin gene multiplex polymerase chain reaction and multiplex ligation-dependant probe amplification analysis showed that both males carried an in-frame deletion of exons 45-55. Segregation analysis revealed two additional asymptomatic boys in this family. Our finding supports previous predictions that exons 45-55 are the optimal multiexon skipping target in antisense gene therapy to transform the severe Duchenne muscular dystrophy into the milder BMD, or even asymptomatic, phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19012301     DOI: 10.1002/mus.21193

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  26 in total

1.  Clinical Utility Gene Card for: Becker muscular dystrophy.

Authors:  David Coote; Mark R Davis; Macarena Cabrera; Merrilee Needham; Nigel G Laing; Kristen J Nowak
Journal:  Eur J Hum Genet       Date:  2018-02-21       Impact factor: 4.246

Review 2.  The Dystrophin Complex: Structure, Function, and Implications for Therapy.

Authors:  Quan Q Gao; Elizabeth M McNally
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

Review 3.  What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2019-07-09       Impact factor: 2.698

4.  Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.

Authors:  Karen Anthony; Sebahattin Cirak; Silvia Torelli; Giorgio Tasca; Lucy Feng; Virginia Arechavala-Gomeza; Annarita Armaroli; Michela Guglieri; Chiara S Straathof; Jan J Verschuuren; Annemieke Aartsma-Rus; Paula Helderman-van den Enden; Katherine Bushby; Volker Straub; Caroline Sewry; Alessandra Ferlini; Enzo Ricci; Jennifer E Morgan; Francesco Muntoni
Journal:  Brain       Date:  2011-11-18       Impact factor: 13.501

5.  Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.

Authors:  Yusuke Echigoya; Kenji Rowel Q Lim; Dyanna Melo; Bo Bao; Nhu Trieu; Yoshitaka Mizobe; Rika Maruyama; Kamel Mamchaoui; Jun Tanihata; Yoshitsugu Aoki; Shin'ichi Takeda; Vincent Mouly; William Duddy; Toshifumi Yokota
Journal:  Mol Ther       Date:  2019-07-26       Impact factor: 11.454

6.  Genotype-phenotype correlation in Becker muscular dystrophy in Chinese patients.

Authors:  Ruiyi Yuan; Junfei Yi; Zhiying Xie; Yimeng Zheng; Miao Han; Yue Hou; Zhaoxia Wang; Yun Yuan
Journal:  J Hum Genet       Date:  2018-07-05       Impact factor: 3.172

7.  Duchenne muscular dystrophy gene therapy: Lost in translation?

Authors:  Dongsheng Duan
Journal:  Res Rep Biol       Date:  2011-03

8.  Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.

Authors:  Yoshitsugu Aoki; Toshifumi Yokota; Tetsuya Nagata; Akinori Nakamura; Jun Tanihata; Takashi Saito; Stephanie M R Duguez; Kanneboyina Nagaraju; Eric P Hoffman; Terence Partridge; Shin'ichi Takeda
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

Review 9.  Emerging genetic therapies to treat Duchenne muscular dystrophy.

Authors:  Stanley F Nelson; Rachelle H Crosbie; M Carrie Miceli; Melissa J Spencer
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

Review 10.  Large in-frame 5' deletions in DMD associated with mild Duchenne muscular dystrophy: Two case reports and a review of the literature.

Authors:  Elizabeth M Gibbs; Florian Barthélémy; Emilie D Douine; Natalie C Hardiman; Perry B Shieh; Negar Khanlou; Rachelle H Crosbie; Stanley F Nelson; M Carrie Miceli
Journal:  Neuromuscul Disord       Date:  2019-09-24       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.